{
    "title": "115_hr5687",
    "content": "The Act titled \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act\" introduces safety-enhancing packaging and disposal features for certain drugs under the Federal Food, Drug, and Cosmetic Act. The Secretary may issue an order requiring the holder of a covered application to implement technologies for packaging or disposal of drugs to mitigate abuse or misuse, after consulting with stakeholders. The order issued by the Secretary may include options for technologies, controls, or measures to reduce the risk of abuse or misuse of the drug listed in the covered application, while ensuring patient access is not unduly burdened. The order issued by the Secretary may provide options for implementing or modifying technologies, controls, or measures to reduce the risk of abuse or misuse of a drug, and may incorporate standards for packaging or disposal. The Secretary may issue an order applicable to a drug class to address concerns about abuse or misuse, with the holder of the application required to submit proposed changes to comply within a specified timeframe. The Secretary may issue an order for a drug class to address abuse or misuse concerns. The holder of the application can request an alternative date within 60 days, and changes must be implemented within 90 days of approval or a longer period approved by the Secretary. The holder of the covered application may propose alternative technologies, controls, or measures for packaging, storage, or disposal, supported by data demonstrating their effectiveness in mitigating abuse or misuse risks. The holder of the covered application can propose alternative technologies, controls, or measures to mitigate drug abuse or misuse risks. Disputes regarding submitted supplements can be appealed using specified dispute resolution procedures. The term 'relevant stakeholders' includes various experts and organizations within the drug industry, such as manufacturers, distributors, healthcare providers, and government agencies. The curr_chunk discusses amendments to the Federal Food, Drug, and Cosmetic Act related to drug approval requirements. It involves various government agencies, addiction specialists, and patient groups. Amendments to the Federal Food, Drug, and Cosmetic Act include requirements for drug approval related to opioids, specifically focusing on technologies, controls, or measures for packaging and disposal to ensure comparable protections to listed drugs. Amendments to the Federal Food, Drug, and Cosmetic Act now include grounds for refusing to approve an Abbreviated New Drug Application if the applicant has not proposed technologies, controls, or measures for packaging or disposal that provide comparable protections to listed drugs. The amendments to the Federal Food, Drug, and Cosmetic Act require technologies, controls, or measures for packaging or disposal to provide comparable protections to listed drugs under section 505-2. Any labeling related to these measures shall not be considered changes to labeling not permissible under the Act. The amendments to the Federal Food, Drug, and Cosmetic Act require technologies, controls, or measures for packaging or disposal to provide comparable protections to listed drugs under section 505-2. Any labeling related to these measures shall not be considered changes to labeling not permissible under the Act. For a covered application submitted under section 505 of the Act, the type of data or information the Secretary of Health and Human Services may request or consider is not limited by subsection (j)(2)(A) of such section 505. The GAO Report, due within 12 months of the Act's enactment, will include evidence on the effectiveness of in-home controlled substance disposal products and packaging technologies. It will also identify barriers to access for patients and consumers not registered under the Controlled Substances Act. The GAO Report will include information on disposal products and packaging technologies for controlled substances, federal oversight, and barriers to access for patients and consumers. The GAO Report will cover federal oversight of controlled substance packaging technologies, including recommended technologies to prevent abuse and diversion of prescribed substances, as well as recommendations on in-home disposal products and packaging technologies. The GAO Report will provide recommendations on federal oversight of in-home controlled substance disposal products and packaging technologies, including evaluating product efficacy and determining responsible agencies for oversight. The House of Representatives passed the bill on June 19, 2018. Karen L. Haas is the Clerk."
}